T cell receptor beta variable 8-2 (pseudogene)Genealiases: TCRBV32S1P · TRBV82
Q-omics provides the consensus-scored TRBV8-2 profile across patient tissues and cancer cell-line models. TRBV8-2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TRBV8-2 is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, TRBV8-2 RNA expression shows 11,472 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, LUSC, and THYM as cancer lineages where TRBV8-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRBV8-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRBV8-2 survival associations across molecular data types. TRBV8-2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRBV8-2 RNA expression–survival associations across cancer types. High TRBV8-2 expression shows unfavorable associations in UCEC, HNSC, MESO and CHOL, but favorable associations in BRCA and SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify UCEC as the clearest survival context for TRBV8-2 RNA expression.
This table summarizes TRBV8-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for TRBV8-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRBV8-2 shows lower tumor expression in LUSC and KICH and higher tumor expression in BRCA, UCEC, THCA and STAD. The LUSC box plot shows higher TRBV8-2 RNA expression in normal versus tumor tissue (log2 FC = −0.325, t-test p < 0.001).
This table shows molecular features associated with TRBV8-2 in patient tissues and cancer cell lines. In patient samples, TRBV8-2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
